Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Zoetis Inc (ZTS) Price & Performance

MONDELEZ INTERNATIONAL INC Common StockTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

MONDELEZ INTERNATIONAL INC Common Stock vs Zoetis Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 2.6× Zoetis Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Zoetis Inc for 70 Days on average.

MDLZZTS
Market Cap
$77.43B$30.20B
Volume
7,695,1046,175,327
Sector
Consumer StaplesHealth
52-Week High
$64.99$147.53
52-Week Low
$51.51$69.09
Typical Hold Time
107 Days70 Days
Enterprise Value
$97.78B$37.76B
Dividend Yield
3.43%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MONDELEZ INTERNATIONAL INC Common Stock

Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.73 exceeding expectations. Revenue growth continues, reaching $38.54B in 2025, while maintaining solid profitability with 8.86% net margin. Recent dividend increase to $0.52 per share and positive news coverage highlight management's confidence in sustained performance.

MDLZ presents a compelling investment case with 76% analyst buy ratings and $70.29 consensus target, offering 16% upside. The company's global brand strength and emerging market momentum support growth, though cocoa cost pressures and competitive snack market pose risks. Cash flow stability and shareholder returns through dividends provide defensive characteristics in uncertain markets.

Zoetis Inc

Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.

The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MDLZ
0% Buy100% Sell
Avg holding period · 107 Days
ZTS

No sentiment data available yet.

About MONDELEZ INTERNATIONAL INC Common Stock

Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.

Read more on MDLZ →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →